Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Other Non-Current Liabilities (2016 - 2025)

United Therapeutics' Other Non-Current Liabilities history spans 17 years, with the latest figure at $223.2 million for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities rose 22.7% year-over-year to $223.2 million; the TTM value through Dec 2025 reached $223.2 million, up 22.7%, while the annual FY2025 figure was $223.2 million, 22.7% up from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $223.2 million at United Therapeutics, up from $214.6 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $223.2 million in Q4 2025 and bottomed at $67.4 million in Q3 2023.
  • The 5-year median for Other Non-Current Liabilities is $99.6 million (2021), against an average of $125.4 million.
  • The largest annual shift saw Other Non-Current Liabilities plummeted 34.88% in 2023 before it soared 133.8% in 2024.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $104.8 million in 2021, then fell by 0.19% to $104.6 million in 2022, then dropped by 25.62% to $77.8 million in 2023, then skyrocketed by 133.8% to $181.9 million in 2024, then increased by 22.7% to $223.2 million in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Other Non-Current Liabilities are $223.2 million (Q4 2025), $214.6 million (Q3 2025), and $207.3 million (Q2 2025).